The Effect of Amifostine on Submandibular Gland Histology after Radiation
Authors:
Open Access
- 15 July 2012
- journal article
- research article
- Published by Hindawi Limited in International Journal of Otolaryngology
- Vol. 2012, 1-7
Abstract
Background. The purpose of this study was to assess the effects of amifostine on submandibular gland histology in patients receiving chemoradiation therapy.Methods.We conducted a retrospective submandibular gland histologic slide review of HNSCC patients receiving chemoradiation for head and neck squamous cell carcinoma with three different levels of amifostine exposure. We used six scoring parameters: fatty replacement, lobular architecture degeneration, interstitial fibrosis, ductal degeneration, acinar degeneration, and inflammatory component presence.Results. Differences in gender, tumor stage, amifostine dose, age, number of days after neck dissection, and smoking history (pack years) exposure were not significant between the three groups, although there was a difference between groups in the primary subsite (). The nonparametric Cuzick's test for histologic parameters with varied amifostine treatment showed no significance among the three groups.Conclusions. Although patients did not receive a full dose of amifostine due to side effects, varying doses of amifostine had no apparent evident cytoprotective effects in three groups of cancer patients treated with primary chemoradiation.
Keywords
This publication has 22 references indexed in Scilit:
- Fifty years of cancer incidence: CI5 I–IXInternational Journal of Cancer, 2010
- A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impactSupportive Care in Cancer, 2010
- Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancerCancer, 2009
- The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphyRadiotherapy and Oncology, 2008
- Amifostine: The First Selective-Target and Broad-Spectrum RadioprotectorThe Oncologist, 2007
- Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: Comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without AmifostineInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Radiation‐induced xerostomia in patients with head and neck cancerCancer, 2006
- Amifostine is a Potent Radioprotector of Salivary Glands in Radioiodine TherapyStrahlentherapie und Onkologie, 2005
- Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunctionInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1994